Melius on SLB (SLB): 'Short-Term Pain, Long-Cycle Gain'

April 24, 2026 1:32 PM

Melius analyst James West reiterated a Buy rating and $70.00 price target on SLB (NYSE: SLB).The analyst comments "We continue ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

StreetInsider

Log in to your account:

Melius on SLB (SLB): 'Short-Term Pain, Long-Cycle Gain'

Categories

Next Articles